Tuberculosis of the future

  • Tjandra Y. Aditama
DOI: https://doi.org/10.13181/mji.v11i3.72
Abstract viewed: 488 times
PDF downloaded: 306 times

Abstract

Beginning and during the 20th century there were several milestones in TB control, including the development of vaccine and chemotherapy. But, as we enter the 21th century, TB continue be a global public health problem and if there is no improvement in TB control, the number of new TB cases is projected to rise to 11 million by 2020. Problems faced include inability to deliver / assure chemotherapy, deficient case finding, inadequate vaccine, rising level of drug resistance, failure to employ preventive chemotherapy and migration, HIV epidemics and nosocomial transmission. As far as recent advances in TB diagnostics, there is a need to find a tool for identification of latent infection, detection of diseases in migrant and other high risk populations, replace or facilitate AFB microscopy, improve the diagnosis of AFB smear-negative cases, and simple tools for determining drugs susceptibility. New diagnostic technologies includes nucleic acid probes, amplification tests, high performances liquid chromatography (HPLC), gas / liquid chromatography (GLC), and automated system for radiometric and non radiometric detection and molecular fingerprinting approach. In the coming years new drugs are needed, especially to shorten the duration of TB treatment or otherwise simplify its completion, improve the treatment of latent TB infection and to be eliminate. MDR-TB. There are some problems in pursue tuberculosis research because of the high investment required to bring a product to market and lack of likely commercial returns. Some new drugs and molecules with promising antimycobacterial activity include Fluoroquinolone, Oxazolidinones, Nitroimidazole, Thiolactomycine, Nitroimidazopyran and Isocitrate lyase inhibitor. To deliver good case finding and treatment, effective TB control program should be implemented in the country, as well as globally. The integration of TB control program with tobacco control program and chronic respiratory diseases control program could be one of the alternative. (Med J Indones 2002; 11: 190-4)

Keywords: tuberculosis, future and recent advances

Downloads

Download data is not yet available.

Author Biography

Tjandra Y. Aditama
Pulmonology Department Faculty of Medicine University of Indonesia / Mycobacterial Laboratory, Persahabatan Hospital, Jakarta, Indonesia
Published
2002-08-01
How to Cite
1.
Aditama TY. Tuberculosis of the future. Med J Indones [Internet]. 2002Aug.1 [cited 2024Jul.3];11(3):190-4. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/72
Issue
Vol. 11 No. 3 (2002): July-September
Section
Review Article

Copyright (c) 2002 Tjandra Y. Aditama

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.